Hence, pharmacological agents that upregulate HO-1 expression have been used as a therapeutic approach for the treatment of obesity and its associated metabolic and cardiovascular diseases [27,29]. The gene discussed is HMOX1; the disease is obesity due to melanocortin 4 receptor deficiency.